文献速递瓣膜外科

INSPIRIS RESILIA主动脉瓣的中期临床与超声心动图结果:与Magna Ease的回顾性比较

Mid-term clinical and echocardiographic results of the INSPIRIS RESILIA aortic valve: a retrospective comparison to the Magna Ease.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2023-01-01

这项回顾性单中心研究纳入2018年1月至2021年7月间置入INSPIRIS(n=488)或Magna Ease(n=463)生物瓣的953例患者,经倾向评分匹配后每组217例。匹配人群中两组30个月生存率相似(INSPIRIS 94% vs Magna Ease 91%,P=0.89),INSPIRIS组免于再入院率更高(94% vs 86%,P=0.014),且出院时、1-3个月及24个月跨瓣平均压差均更低。作者结论认为INSPIRIS与Magna Ease相比安全且2年血流动力学表现良好,长期随访正在进行中。

要点

  • 匹配人群中INSPIRIS组30个月生存率94% vs Magna Ease组91%,差异无统计学显著(P=0.89)。
  • INSPIRIS组免于再入院率94% vs Magna Ease组86%(P=0.014)。
  • INSPIRIS组跨瓣平均压差在出院时(约10 vs 14 mmHg)、1-3个月(约10 vs 12 mmHg)及24个月(约11 vs 17 mmHg)均低于Magna Ease组(均P<0.001)。

核心结论

  • 本研究是INSPIRIS与Magna Ease瓣膜的最大规模比较评估,显示2年时临床结局安全且血流动力学表现良好,长期随访正在进行中。

研究设计与样本

  • 回顾性单中心研究,纳入2018年1月至2021年7月间置入INSPIRIS(n=488)或Magna Ease(n=463)生物瓣的953例患者,临床终点采用倾向评分匹配分析,超声随访数据采用配对分析和线性混合效应模型比较。

主要发现

  • 匹配人群每组217例,短期结局无显著差异,30个月生存率INSPIRIS组94% vs Magna Ease组91%(P=0.89)。
  • INSPIRIS组免于再入院率94% vs Magna Ease组86%(P=0.014)。
  • 配对分析中INSPIRIS组跨瓣平均压差在出院时约10 vs 14 mmHg、1-3个月约10 vs 12 mmHg、24个月约11 vs 17 mmHg,均低于Magna Ease组(均P<0.001),且平均跨瓣压差随时间演变显著低于Magna Ease组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The INSPIRIS aortic valve combines the RESILIA proprietary tissue preservation process and an expandable stent frame to benefit future transcatheter valve-in-valve procedures. As the INSPIRIS valve became commercially available in 2017, mid-term outcome reports are scarce. We aimed to evaluate mid-term safety and echocardiographic performance of the INSPIRIS valve in comparison to its predecessor, the Carpentier Edwards Perimount Magna Ease (ME). METHODS: This study was a retrospective single-centre study. Clinical results included early postoperative outcomes, mid-term mortality and readmission for cardiovascular cause or stroke. Echocardiographic follow-up (FU) was performed at discharge and 1-3, 6, 12 and 24 months. Clinical end point analyses were accomplished with a propensity score matching analysis and FU echocardiographic data comparisons using pairwise analyses and linear mixed-effect models. RESULTS: We included 953 patients who received an INSPIRIS (n = 488) or ME (n = 463) bioprosthesis between January 2018 and July 2021. In the matched population (n = 217 per group), no significant difference in short-term outcomes was observed, survival was similar at 30 months (INSPIRIS: 94% vs ME: 91%, P = 0.89), but freedom from readmission was higher in the INSPIRIS group (94% vs 86%, P = 0.014). INSPIRIS valves had a lower gradient at discharge (∼10 vs 14 mmHg, P < 0.001), 1-3 months (∼10 vs 12 mmHg, P < 0.001) and 24 months (∼11 vs 17 mmHg, P < 0.001) in paired analyses and significantly lower evolution of mean transvalvular gradients compared to ME. CONCLUSIONS: This study represents the largest comparative evaluation of the INSPIRIS to the ME valves, which demonstrated safe clinical outcomes and favourable haemodynamic performance at 2 years. Long-term FU is underway.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Bernard J, Georges G, Hecht S, et al. Mid-term clinical and echocardiographic results of the INSPIRIS RESILIA aortic valve: a retrospective comparison to the Magna Ease. Interdiscip Cardiovasc Thorac Surg. 2023. PMID: 37462610. doi:10.1093/icvts/ivad117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。